Advances in targeted therapy for unresectable melanoma: new drugs and combinations.

Mengze Hao,Fengju Song,Xiaoling Du,Guowen Wang,Yun Yang,Kexin Chen,Jilong Yang
DOI: https://doi.org/10.1016/j.canlet.2014.12.050
IF: 9.756
2015-01-01
Cancer Letters
Abstract:Melanoma is the most deadly cutaneous cancer primarily derived from melanocytes with a poor prognosis in advanced stage. The therapy regimen for early stage melanoma patients is surgical resection with adjuvant IFN-alpha-2b therapy. For metastatic lesions, standard chemotherapy such as dacarbazine (DTIC) has not achieved a satisfying response rate. Therefore, new approaches to manage this deadly disease are highly expected to enhance the cure rate and to extend clinical benefits to patients with unresectable melanoma. Fortunately, the targeted therapeutic drugs and immunotherapy such as vemurafenib, dabrafenib, ipilimumab, and trametinib have shown their special advantage in the treatment of advanced melanoma. This article is to overview the advances in targeted therapy for unresectable melanoma patients.
What problem does this paper attempt to address?